A detailed approach on multiple myeloma and its treatment


  • A. Veerendra Sagar Division of Pharmacology, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India
  • Ch. Divya . Division of Pharmacology, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India
  • A. Prathyusha Division of Pharmacology, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India
  • P. Haritha Division of Pharmacology, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India


Myeloma, Plasma, Tumor, Monoclonal gammopathy, Bone marrow


Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is composed of several types of cells that work together to fight infections and other diseases. Lymphocytes are the main cell type of the immune system. There are 2 major types of lymphocytes: T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies that help the body attack and kill germs. Lymphocytes can be found in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue inside some hollow bones. In addition to plasma cells, normal bone marrow has cells that make the different normal blood cells. When plasma cells become cancerous and grow out of control they can produce a tumor called a plasmacytoma. These tumors generally develop in a bone, but they are also rarely found in other tissues. If there is only a single plasma cell tumor, it is called an isolated plasmacytoma. When there is more than one plasma cell tumor, it is called ‘multiple myeloma’. There are lot of plasma cell abnormalities, but multiple myeloma causes severe bone pain, so here we covered detailed notes on the disease and its treatment strategies.


American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012.

Anderson KC, Rajkumar SV, Bergsagel PL, Reece DE. Myeloma in, Hematology 2005, American Society of Hematology, pages 340-359. Available at www.asheducationbook.org.

Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.

Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 May:3412-3420.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975- 2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

Kyle RA, Rajkumar SV. Multiple myeloma. New Eng J Med. 2004;351:1860-1873.

Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02.

National Cancer Institute. Physician Data Query (PDQ). Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. acceced at www.nci.org.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Multiple myeloma. V.1.2013.

Munshi NC, Anderson KC. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:1997−2032. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17;364(11):1046-1060.

Raje N, Hideshima T, Anderson KC. Plasma cell tumors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E. Cancer Medicine 6. Hamilton, Ontario: BC Decker; 2003:2219-2244.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG. Clinical Oncology. Philadelphia, PA. Elsevier: 2008:2323-2340.

Sirohi B, Powles R. Multiple Myeloma. Lancet 2004;363:875-887.

Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol. 2005;132:410-452.

Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.

Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312-1322.

Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009;43:417-422.

Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.

Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584-593.

Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991-995.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374 (9686):324-39.

Paul M, Walker F, Bear RA. Plasmapheresis therapy in a patient with multiple myeloma. Can Med Assoc J 1982;127(10):956.

Matus RE, Leifer CE, MacEwen EG, Hurvitz AI. Prognostic factors for multiple myeloma in the dog. J Am Vet Med Assoc 1986;11(188):1288-92.

MacEwan EG, Hurvitz AI. Diagnosis and Management of Monoclonal Gammopathies. Vet Clin North American Small Animal Practice 1977;7:119.

Collins CD. Problems monitoring response in multiple myeloma. Cancer Imaging 2005;5 (Spec No A):S119-26. doiP10.1102/1470-7330.2005.0033.

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57.

Longo, Dan (2012). Harrison's Principles of Internal Medicine 18th Edition. Mc Graw Hill Medical. p. 938. ISBN 978-0-07-174889-6.

Hargreaves RM, Lea JR, Griffiths H, et al. Immunological factors and risk of infection in plateau phase myeloma (stable phase). J Clin Pathol. 1995;48(3):260-6.

Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. "Multiple myeloma". Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. p. 455. ISBN 1-4160-2973-7.

Durie BGM. Treatment of Myeloma - Are We Making Progress? N Engl J Med. 2008;359(9):964-6.

Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150(4):863-9.

Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83.

Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27:4585-90.




How to Cite

Sagar, A. V., ., C. D., Prathyusha, A., & Haritha, P. (2017). A detailed approach on multiple myeloma and its treatment. International Journal of Basic & Clinical Pharmacology, 2(6), 671–676. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1347



Review Articles